Your browser doesn't support javascript.
loading
Recurrent Kounis Syndrome: A Case Report and Literature Review.
Brancaccio, Raffaele; Bonzano, Laura; Cocconcelli, Alessia; Boyko, Rostyslav; Ienopoli, Giuseppe; Motolese, Alberico.
Afiliação
  • Brancaccio R; Dermatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio nell'Emilia, Italy.
  • Bonzano L; Dermatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio nell'Emilia, Italy.
  • Cocconcelli A; Dermatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio nell'Emilia, Italy.
  • Boyko R; Postgraduate School of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Ienopoli G; Postgraduate School of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Motolese A; Dermatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio nell'Emilia, Italy.
J Clin Med ; 13(6)2024 Mar 13.
Article em En | MEDLINE | ID: mdl-38541873
ABSTRACT
Kounis syndrome is a condition where inflammatory cells (mostly mast cells with the contribution of macrophages and T-lymphocytes) cause an acute coronary syndrome. Kounis syndrome comes in four variants type I in patients with normal coronary arteries; type II in patients with inactive pre-existing atheromatous disease; type III in patients with pre-existing coronary artery stenting; type IV in patients with a pre-existing coronary artery bypass. Recently, we came across a case of recurrent type I Kounis syndrome in our clinical practice. The purpose of the paper is to present our case and conduct a review using the Pubmed scientific database about the most relevant cases of recurrent Kounis syndrome. This review shows that recurrent Kounis syndrome is a rare condition and is mostly associated with Kounis syndrome type III. Recurrent Kounis syndrome may be also triggered by vaccination and it could be associated with chronic spontaneous urticaria. In the last condition, therapy is represented by second-generation anti-histamines and corticosteroids, but also by an anti-IgE monoclonal antibody (omalizumab) in the recalcitrant cases.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália